EU Solicits Stakeholder Views On Fairness And Structure Of EMA’s Fee System
Executive Summary
Stakeholders finally have a chance to air their views about the European Medicine Agency’s fee and remuneration system, particularly whether it is “fair, cost-based and not unduly complex.”
You may also be interested in...
Keep It Simple: EU Consults On Future Design Of EMA’s Fee System
Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.
UK Industry Gets More Time To Adapt To Post-Brexit Import Rules
The BioIndustry Association has welcomed a decision to delay the deadline for compliance with new regulations on the classification of imported materials used in drug production, but says the border rules are still not proportionate for life science products.